 |
138 Diseases |  |
93 Trials |
|
93 Trials |  |
2194 News |  |
| «12345678910111213...3334» |
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Feb 22, 2024
P3, N=3100, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting
- An Unusual Case of Metastatic Prostate Cancer Presenting With Atypical Metastases to Mediastinal Lymph Nodes (San Diego Convention Center, Room 6E (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_8239;
Mediastinal lymph node metastasis from PCa is a rare but significant event, impacting patient outcomes and management. Further research is crucial to unravel lymphatic spread mechanisms and improve diagnostic and therapeutic approaches for this patient subset.
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
No Pressure: An Unusual Case of PFO Induced Hypoxia (San Diego Convention Center, Area I (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6424;
pneumonectomy, dilated descending aorta, compression from the abdomen, kyphosis) have been described. Knowledge of this phenomenon can be critical in making a diagnosis in an otherwise challenging case.
- |||| Kisqali (ribociclib) / Novartis
Trial primary completion date: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P3, N=3100, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Knowledge of this phenomenon can be critical in making a diagnosis in an otherwise challenging case. Trial primary completion date: Jul 2028 --> Sep 2029
- || leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty (clinicaltrials.gov) - Feb 15, 2024
P4, N=80, Recruiting, Sponsor: Takeda
Trial primary completion date: Jul 2028 --> Sep 2029 Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Jan 2024 --> May 2025
- || Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date, Combination therapy: SAVE: Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (clinicaltrials.gov) - Feb 15, 2024
P2, N=202, Recruiting, Sponsor: Cancer Research Antwerp
Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Jan 2024 --> May 2025 Trial completion date: Sep 2022 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Aug 2025
- | Phase classification, Trial completion date, Trial primary completion date: First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov) - Feb 15, 2024
P2, N=31, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Sep 2022 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Aug 2025 Phase classification: P2a --> P2 | Trial completion date: May 2026 --> Jan 2027 | Trial primary completion date: May 2025 --> Jan 2027
- || Nubeqa (darolutamide) / Bayer, Orion Corp, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
Review, Journal: Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology. (Pubmed Central) - Feb 15, 2024
The panel reached a consensus on 18 statements based on recent evidence and expert insights. These consensus statements serve as a practical recommendation for clinicians in Hong Kong, and possibly the Asia-Pacific region, in the management of cardiometabolic toxicities of ADT or AR axis-targeted therapies in men with PCa.
- ||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open, HEOR: RecoverPC: Relugolix vs GnRH Agonist in Quality of Life (clinicaltrials.gov) - Feb 14, 2024
P2, N=110, Recruiting, Sponsor: Dana-Farber Cancer Institute
These consensus statements serve as a practical recommendation for clinicians in Hong Kong, and possibly the Asia-Pacific region, in the management of cardiometabolic toxicities of ADT or AR axis-targeted therapies in men with PCa. Not yet recruiting --> Recruiting
- | leuprolide acetate for depot suspension / Generic mfg., megestrol / Generic mfg.
Trial completion: Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine (clinicaltrials.gov) - Feb 6, 2024
P4, N=126, Completed, Sponsor: Children's Hospital of Fudan University
Not yet recruiting --> Recruiting Recruiting --> Completed
- | docetaxel / Generic mfg.
Trial completion, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Jan 31, 2024
P1, N=20, Completed, Sponsor: Medical University of South Carolina
Recruiting --> Completed Active, not recruiting --> Completed
- | danazol vaginal cream / FemmePharma, Covis Pharma
Preclinical, Journal: Therapeutic Effects of Melatonin in Female Mice with Central Precocious Puberty by Regulating the Hypothalamic Kiss-1/Kiss1R System. (Pubmed Central) - Jan 30, 2024
Melatonin suppressed the expressions of Kiss-1, Kiss1R and GnRH in the hypothalamus, and the expression of GnRHR in the pituitary of the female CPP mice. Our results suggest that melatonin can inhibit the hypothalamic-pituitary-gonadal (HPG) axis by down-regulating the Kiss-1/Kiss1R system, thereby treating CPP in female mice.
- ||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed, Adverse events: REPLACE-CV: Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (clinicaltrials.gov) - Jan 28, 2024
P3, N=2250, Active, not recruiting, Sponsor: Myovant Sciences GmbH
Our results suggest that melatonin can inhibit the hypothalamic-pituitary-gonadal (HPG) axis by down-regulating the Kiss-1/Kiss1R system, thereby treating CPP in female mice. Recruiting --> Active, not recruiting
- CARDIAC REHABILITATION FOR TRANSGENDER PATIENT: CASE REPORT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_473;
Interestingly, CR did not improve body composition in this patient. Despite the clear positive impact that CR had on exercise capacity, body composition appeared to worsen.
- |||| New P2 trial: ESCALATE: Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients (clinicaltrials.gov) - Jan 25, 2024
P2, N=124, Not yet recruiting, Sponsor: National Taiwan University Hospital
- | leuprolide acetate for depot suspension / Generic mfg.
Preclinical, Journal: Estrogen-induced glial IL-1? mediates extrinsic retinal ganglion cell vulnerability in murine Nf1 optic glioma. (Pubmed Central) - Jan 17, 2024
neutralization and leuprolide-mediated estrogen suppression decrease IL-1? expression and ameliorate RGC dysfunction, providing preclinical proof-of-concept evidence supporting novel neuroprotective strategies for NF1-OPG-induced vision loss.
- bicalutamide / Generic mfg.
Screen C: Local management with surgery A Randomized Comparison of 9 months (EGPT) - Jan 15, 2024 - Abstract #EAU2024EAU_2251;
- enzalutamide capsule / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Screen E: Prostate cancer Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk biochemically recurrent prostate cancer (BCR) following radical prostatectomy (RP) or radiation therapy (RT): EMBARK post hoc analysis (EGPT) - Jan 15, 2024 - Abstract #EAU2024EAU_1498;
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion date, Trial primary completion date: Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW (clinicaltrials.gov) - Jan 11, 2024
P1, N=20, Recruiting, Sponsor: Johns Hopkins University
expression and ameliorate RGC dysfunction, providing preclinical proof-of-concept evidence supporting novel neuroprotective strategies for NF1-OPG-induced vision loss. Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: The multifactorial aetiology and management of premenstrual dysphoric disorder with leuprorelin acetate. (Pubmed Central) - Jan 6, 2024
As the psychological nature and consequences of PMDD often seem indistinguishable from symptoms of other mental health difficulties, this condition presents distinct diagnostic challenges for healthcare professionals. It is crucial to establish the correct diagnosis using clearly defined criteria because if it is left untreated, it can cause considerable impairment to the woman's quality of life.
- || Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
Trial completion date, Trial primary completion date: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jan 4, 2024
P2, N=82, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
It is crucial to establish the correct diagnosis using clearly defined criteria because if it is left untreated, it can cause considerable impairment to the woman's quality of life. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Trial primary completion date: NePtune: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (clinicaltrials.gov) - Jan 4, 2024
P2, N=32, Recruiting, Sponsor: Rana McKay, MD
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
- | Firmagon (degarelix) / Astellas, Ferring, NN1213 / Novo Nordisk
Trial completion date, Monotherapy: High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Dec 31, 2023
P=N/A, N=163, Active, not recruiting, Sponsor: Stanford University
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Trial completion date, Trial primary completion date: URONCOR 06-24: Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624 (clinicaltrials.gov) - Dec 31, 2023
P3, N=534, Recruiting, Sponsor: Instituto de Investigaci
- | leuprolide acetate for depot suspension / Generic mfg.
New trial: PROSTSIZE: Prostatic Size Reduction Following of Leuprorelin Acetate (clinicaltrials.gov) - Dec 27, 2023
P=N/A, N=40, Not yet recruiting, Sponsor: Consorci Sanitari de Terrassa
- | leuprolide acetate for depot suspension / Generic mfg., abiraterone acetate / Generic mfg.
Journal: Scalp nodules as the first presentation of prostate cancer: A CARE-compliant article. (Pubmed Central) - Dec 24, 2023
Cutaneous metastasis, especially scalp metastasis from prostate cancer, is extremely rare. If there is a rash or nodule on the skin, it is necessary to evaluate it carefully and to confirm it through a biopsy.
- || Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial initiation date, HEOR: RecoverPC: Relugolix vs GnRH Agonist in Quality of Life (clinicaltrials.gov) - Dec 19, 2023
P2, N=110, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
If there is a rash or nodule on the skin, it is necessary to evaluate it carefully and to confirm it through a biopsy. Initiation date: Aug 2023 --> Jan 2024
- || leuprolide acetate for depot suspension / Generic mfg.
Trial completion: A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) (clinicaltrials.gov) - Dec 17, 2023
P3, N=45, Completed, Sponsor: AbbVie
Initiation date: Aug 2023 --> Jan 2024 Active, not recruiting --> Completed
- | Kisqali (ribociclib) / Novartis
FDA event, Journal, Metastases: FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer. (Pubmed Central) - Dec 17, 2023
The known mechanism of action, biologic rationale, and clinical information available adequately demonstrate that the efficacy and safety of ribociclib+AI/fulvestrant are similar in male and female patients. This article summarizes the FDA's decision-making and data supporting the approval of ribociclib in male patients with breast cancer, and discusses regulatory insights.
- leuprolide acetate for depot suspension / Generic mfg.
Pattern of testosterone recovery after androgen deprivation therapy. (Level 1, West Hall; Poster Bd # N21) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_480;
Risk factors for non-recovery include age >80 years and long-term ADT use. Surprisingly, among men who achieved testosterone recovery, there was no difference in TTR with respect to ADT duration.
- Erleada (apalutamide) / J&J
Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial. (Level 1, West Hall; Poster Bd # N17) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_476;
P2
As 30% of patients declined an additional 12 months of adjuvant treatment, Part B of the study was underpowered to detect a difference between treatment arms. Subsequent studies will evaluate clinical and molecular predictors of bPFS.
- enzalutamide capsule / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures. (Level 1, West Hall; Poster Bd # N4) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_463;
P3
Further, the SA PROs were similar between ENZ + L and P + L, implying there is no further SA burden when adding ENZ to androgen-deprivation therapy. Clinical trial information: NCT02319837.
- leuprolide acetate for depot suspension / Generic mfg.
Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular toxicity from androgen deprivation therapy in men with prostate cancer. (Level 1, West Hall; Poster Bd # N3) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_462;
CHIP variants, identified in 28% of this cohort, was associated with increased odds of experiencing a rise in CV risk score. Notably, Black men were more likely to harbor CHIP and experience increased CV risk after 6 months of leuprolide, respectively.
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): An initial analysis of patient treatment preferences and quality of life. (Level 1, West Hall; Poster Bd # M14) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_451;
P4
Relugolix, compared with leuprolide, mitigated acute urinary toxicity from XRT, perhaps due to superior castration resulting in greater prostate gland downsizing and less obstructive uropathy. Longer-term follow up is ongoing, and primary CV toxicity endpoint is expected to be complete in 2024.
- Erleada (apalutamide) / J&J
Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results of a phase II clinical trial. (Level 1, West Hall; Poster Bd # H3) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_358;
P2
The regimen was well tolerated, with 90% of patients completing six months of ADT and at least one next-generation ARSI. Further prospective data will evaluate whether dual ARSIs are necessary and the extent to which SBRT with short-course AAT outperforms SBRT with ADT monotherapy in this patient population.
- Erleada (apalutamide) / J&J
Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer. (Level 1, West Hall; Poster Bd # G13) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_348;
P2
Although a small trial, a majority of patients with molecular imaging defined de novo oligometastatic prostate cancer treated with primary and metastasis-directed therapy with intensified systemic therapy of limited duration remained free of progression with a recovered testosterone off all active therapy. Clinical trial information: NCT03298087.
- enzalutamide capsule / Generic mfg.
Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK. (Level 1, West Hall; Poster Bd # G6) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_342;
P3
No difference in MFS was observed in the no suspension group, but firm conclusions were precluded by the limited number of pts who did not suspend tx with enza combo. Pts who suspended tx had higher rates of prior RP vs those who did not.
- leuprolide acetate for depot suspension / Generic mfg.
Impact of combined novel hormonal agents on testosterone levels of patients with prostate cancer undergoing treatment with leuprorelin. (Level 1, West Hall; Poster Bd # D10) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_283;
However, when analyzing deeper testosterone suppression levels, the addition of NHA was associated with statistically significant difference in the rate of patients with testosterone < 20 ng/mL. These results reinforce the importance of intense hormonal treatment in pts with PCa receiving leuprorelin.
- Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer. (Level 1, West Hall; Poster Bd # C20) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_273;
The combination has a favorable safety and tolerability profile with no new safety concerns. No new DDI concerns were raised.
- enzalutamide capsule / Generic mfg.
Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study. (Level 3, Ballroom) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_149;
P3
However, in the no suspension group, enza mono prolonged MFS vs leuprolide alone, though the number of MFS events was limited (n=4). Pts with prior RP were also more likely to reach the PSA threshold for tx suspension.
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Electrochemical Modification of Polypeptides at Selenocysteine. (Pubmed Central) - Dec 7, 2023
The power of e-SE is highlighted through late-stage C-terminal modification of the FDA-approved cancer drug leuprolide, and assembly of a library of anti-HER2 affibody-conjugates bearing complex cargoes. Following assembly by e-SE, the utility of functionalized affibodies for in vitro imaging and targeting of HER2 positive breast and lung cancer cell lines is also demonstrated.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Trial primary completion date: NePtune: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (clinicaltrials.gov) - Dec 5, 2023
P2, N=32, Recruiting, Sponsor: Rana McKay, MD
Following assembly by e-SE, the utility of functionalized affibodies for in vitro imaging and targeting of HER2 positive breast and lung cancer cell lines is also demonstrated. .
- | tamoxifen / Generic mfg.
Trial completion date, Trial primary completion date: Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial) (clinicaltrials.gov) - Dec 4, 2023
P3, N=224, Recruiting, Sponsor: Seoul National University Hospital
. Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Brown Adipose Tissue Activity in Pre- and Postmenopausal Women (clinicaltrials.gov) - Dec 4, 2023
P=N/A, N=72, Completed, Sponsor: University of Colorado, Denver
Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024 Recruiting --> Completed | Trial completion date: Aug 2023 --> May 2023 | Trial primary completion date: Aug 2023 --> May 2023
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Rubraca (rucaparib) / Pharma& Schweiz
Enrollment closed, Enrollment change, Metastases: CASPAR: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (clinicaltrials.gov) - Dec 3, 2023
P3, N=61, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed | Trial completion date: Aug 2023 --> May 2023 | Trial primary completion date: Aug 2023 --> May 2023 Suspended --> Active, not recruiting | N=1002 --> 61
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Aqueous remote loading of model cationic peptides in uncapped poly(lactide-co-glycolide) microspheres for long-term controlled release. (Pubmed Central) - Dec 1, 2023
Suspended --> Active, not recruiting | N=1002 --> 61 Here, we formulated drug-free microspheres from two kinds of uncapped poly(lactide-co-glycolides) (PLGAs), i.e., ring-opening polymerized Expansorb DLG 50-2A (50/50, 11.2
- | Visanne (dienogest) / Mochida, Bayer
New P3 trial, Surgery: ENDOSafe: Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (clinicaltrials.gov) - Nov 27, 2023
P3, N=100, Recruiting, Sponsor: Universitas Diponegoro
- | Firmagon (degarelix) / Astellas, Ferring, NN1213 / Novo Nordisk
Phase classification, Monotherapy: High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Nov 21, 2023
P=N/A, N=163, Active, not recruiting, Sponsor: Stanford University
Here, we formulated drug-free microspheres from two kinds of uncapped poly(lactide-co-glycolides) (PLGAs), i.e., ring-opening polymerized Expansorb DLG 50-2A (50/50, 11.2 Phase classification: P1/2 --> P=N/A
- || Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company, Cetrotide (cetrorelix) / EMD Serono, Mifeprex (mifepristone) / Danco Laboratories
Review, Journal: Novel Approaches to Possible Targeted Therapies and Prophylaxis of Uterine Fibroids. (Pubmed Central) - Nov 21, 2023
Three different nosological forms of the disease associated with driver mutations in the MED12, HMGA2, and FH genes should be considered when developing or prescribing drugs. For example, synthetic inhibitors and vaccines based on matrix metalloproteinases MMP11 and MMP16 are expected to be effective only for the prevention of the occurrence of MED12-dependent nodules.
- | Xtandi (enzalutamide) / Pfizer, Astellas
Enrollment open: ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov) - Nov 18, 2023
P4, N=228, Recruiting, Sponsor: University of Colorado, Denver
For example, synthetic inhibitors and vaccines based on matrix metalloproteinases MMP11 and MMP16 are expected to be effective only for the prevention of the occurrence of MED12-dependent nodules. Not yet recruiting --> Recruiting